Page 100 - 20211214_OHKF_Health_Finance_Research_Report_E (1)

Overall, the GOPC-PPP has received positive feedback from medical professional bodies,
patients, private doctors, and the community partners. The patient satisfaction rate was
reported to be 90% in a patient survey in 2017 (Legislative Council Panel on Health Services,
2018b). However, an interim review by the HA published in 2016 pointed out that the drug list
was insufficient to address the clinical conditions associated with Diabetes Melltius (DM) and
hypertension. The interim review also found that the GOPC-PPP increased the administrative
workload of participating service providers, which could have disincentivised participation.
Stakeholders engaged by the OHKF research team also identified additional workload and
unattractive financial incentives as barriers to private sector participation, particularly as the
compensation offered is not perceived to balance out the extra workload (see Chapter 4.1).

Separately, an external review journal article published in 2021 from the Hong Kong
Polytechnic University discussed some limitations of the GOPC-PPP programme as follows
(Lau & Fong, 2021):

• Lack of integrated care to support holistic needs of DM and hypertension patients and
patients with more than one chronic disease

• Patients must pay additional out-of-pocket expenses for items not covered in the
programme, including medications

• Lack of quality standardisation of private providers

In moving forward, the identified challenges highlighted in relation to the GOPC-PPP scheme
highlights the need for various areas of improvement that should be considered, including the
need for redesigning for integration of services for chronic diseases management, reviewing
the incentives to motivate participation of suitably trained doctors, and the quality assurance
mechanisms.

98